FDA has approved 26 new molecular entities this year

12/12/2013 | Medical Marketing & Media

Twenty-six new molecular entities have been approved so far in 2013 in the U.S., said Dr. Richard Moscicki, the deputy center director for science operations at the FDA's Center for Drug Evaluation and Research. Both approvals and applications are down from last year. Rare disease indications accounted for 36% of the new drug approvals, and three of the approved medications this year were cleared with the breakthrough therapy status.

View Full Article in:

Medical Marketing & Media

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Counsel I – Clinical Contracts
Gilead Sciences
Foster City, CA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Vice President, Idaho Regional Director
Boise, ID